Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

Nicolas Larmonier, Nona Janikashvili, Collin James Lacasse, Claire B Larmonier, Jessica Cantrell, Elaine Situ, Tamara Lundeen, Bernard Bonnotte, Emmanuel Katsanis

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well as stimulating effects of this drug on CD4+ and CD8+ T lymphocytes or dendritic cells have been reported. In the current study, we have investigated the influence of imatinib mesylate on CD4+CD25 +FoxP3+ regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance. Used at concentrations achieved clinically, imatinib impaired Treg immunosuppressive function and FoxP3 expression but not production of IL-10 and TGF-β in vitro. Imatinib significantly reduced the activation of the transcription factors STAT3 and STAT5 in Treg. Analysis of Treg TCR-induced signaling cascade indicated that imatinib inhibited phosphorylation of ZAP70 and LAT. Substantiating these observations, imatinib treatment of mice decreased Treg frequency and impaired their immunosuppressive function in vivo. Furthermore, imatinib mesylate significantly enhanced antitumor immune responses to dendritic cell-based immunization against an imatinib-resistant BCR-ABL negative lymphoma. The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)6955-6963
Number of pages9
JournalJournal of Immunology
Volume181
Issue number10
StatePublished - Nov 15 2008

Fingerprint

Active Immunotherapy
Regulatory T-Lymphocytes
Neoplasms
Immunosuppressive Agents
Dendritic Cells
Imatinib Mesylate
STAT5 Transcription Factor
Peripheral Tolerance
STAT3 Transcription Factor
Philadelphia Chromosome
Gastrointestinal Stromal Tumors
Interleukin-10
Protein-Tyrosine Kinases
Immunotherapy
Immunization
Lymphoma
Leukemia

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. / Larmonier, Nicolas; Janikashvili, Nona; Lacasse, Collin James; Larmonier, Claire B; Cantrell, Jessica; Situ, Elaine; Lundeen, Tamara; Bonnotte, Bernard; Katsanis, Emmanuel.

In: Journal of Immunology, Vol. 181, No. 10, 15.11.2008, p. 6955-6963.

Research output: Contribution to journalArticle

Larmonier, N, Janikashvili, N, Lacasse, CJ, Larmonier, CB, Cantrell, J, Situ, E, Lundeen, T, Bonnotte, B & Katsanis, E 2008, 'Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors', Journal of Immunology, vol. 181, no. 10, pp. 6955-6963.
Larmonier, Nicolas ; Janikashvili, Nona ; Lacasse, Collin James ; Larmonier, Claire B ; Cantrell, Jessica ; Situ, Elaine ; Lundeen, Tamara ; Bonnotte, Bernard ; Katsanis, Emmanuel. / Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. In: Journal of Immunology. 2008 ; Vol. 181, No. 10. pp. 6955-6963.
@article{cd87b66b3b4e463f98c94d4aca2d53e0,
title = "Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors",
abstract = "Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well as stimulating effects of this drug on CD4+ and CD8+ T lymphocytes or dendritic cells have been reported. In the current study, we have investigated the influence of imatinib mesylate on CD4+CD25 +FoxP3+ regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance. Used at concentrations achieved clinically, imatinib impaired Treg immunosuppressive function and FoxP3 expression but not production of IL-10 and TGF-β in vitro. Imatinib significantly reduced the activation of the transcription factors STAT3 and STAT5 in Treg. Analysis of Treg TCR-induced signaling cascade indicated that imatinib inhibited phosphorylation of ZAP70 and LAT. Substantiating these observations, imatinib treatment of mice decreased Treg frequency and impaired their immunosuppressive function in vivo. Furthermore, imatinib mesylate significantly enhanced antitumor immune responses to dendritic cell-based immunization against an imatinib-resistant BCR-ABL negative lymphoma. The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy.",
author = "Nicolas Larmonier and Nona Janikashvili and Lacasse, {Collin James} and Larmonier, {Claire B} and Jessica Cantrell and Elaine Situ and Tamara Lundeen and Bernard Bonnotte and Emmanuel Katsanis",
year = "2008",
month = "11",
day = "15",
language = "English (US)",
volume = "181",
pages = "6955--6963",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

AU - Larmonier, Nicolas

AU - Janikashvili, Nona

AU - Lacasse, Collin James

AU - Larmonier, Claire B

AU - Cantrell, Jessica

AU - Situ, Elaine

AU - Lundeen, Tamara

AU - Bonnotte, Bernard

AU - Katsanis, Emmanuel

PY - 2008/11/15

Y1 - 2008/11/15

N2 - Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well as stimulating effects of this drug on CD4+ and CD8+ T lymphocytes or dendritic cells have been reported. In the current study, we have investigated the influence of imatinib mesylate on CD4+CD25 +FoxP3+ regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance. Used at concentrations achieved clinically, imatinib impaired Treg immunosuppressive function and FoxP3 expression but not production of IL-10 and TGF-β in vitro. Imatinib significantly reduced the activation of the transcription factors STAT3 and STAT5 in Treg. Analysis of Treg TCR-induced signaling cascade indicated that imatinib inhibited phosphorylation of ZAP70 and LAT. Substantiating these observations, imatinib treatment of mice decreased Treg frequency and impaired their immunosuppressive function in vivo. Furthermore, imatinib mesylate significantly enhanced antitumor immune responses to dendritic cell-based immunization against an imatinib-resistant BCR-ABL negative lymphoma. The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy.

AB - Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well as stimulating effects of this drug on CD4+ and CD8+ T lymphocytes or dendritic cells have been reported. In the current study, we have investigated the influence of imatinib mesylate on CD4+CD25 +FoxP3+ regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance. Used at concentrations achieved clinically, imatinib impaired Treg immunosuppressive function and FoxP3 expression but not production of IL-10 and TGF-β in vitro. Imatinib significantly reduced the activation of the transcription factors STAT3 and STAT5 in Treg. Analysis of Treg TCR-induced signaling cascade indicated that imatinib inhibited phosphorylation of ZAP70 and LAT. Substantiating these observations, imatinib treatment of mice decreased Treg frequency and impaired their immunosuppressive function in vivo. Furthermore, imatinib mesylate significantly enhanced antitumor immune responses to dendritic cell-based immunization against an imatinib-resistant BCR-ABL negative lymphoma. The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=58149187113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149187113&partnerID=8YFLogxK

M3 - Article

C2 - 18981115

AN - SCOPUS:58149187113

VL - 181

SP - 6955

EP - 6963

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -